Imugene soars 30pc on gastric cancer trial

MELBOURNE: An ASX-listed immuno-oncology biotechnology company is providing fresh hope for gastric cancer ...

To read the full story...SUBSCRIBE NOW

Existing Subscribers Login Below:

Log In